Bora Advances in the U.S. Market with $30 Million Acquisition of Sterile Injectable Plant

Bora pharmaceuticals) has taken another significant step in its expansion into the U.S. market by announcing on June 20 the acquisition of Emergent BioSolutions’ sterile injectable plant in Camden, Maryland, for $30 million (approximately NT$960 million). Bora stated that this acquisition marks its first sterile injectable facility, significantly enhancing its global contract development and manufacturing organization (CDMO) capabilities and underscoring its strong ambitions in the U.S.